Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation
Antibody Therapeutics · 16.10.2025 · 8 (4) · 350-363
DOI: 10.1093/abt/tbaf025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 04.11.2025. Verfasst von Jessica R Pickett und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Environment and Science, Griffith University, 170 Kessels Road, Nathan, Queensland 4111, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, National Heart Foundation of Australia, Promoting Women Fellowship from the University of Queensland.
Abstract (Originalsprache)
Objective
Antibodies against vascular cell adhesion molecule (VCAM)-1 represent an attractive strategy for atherosclerosis and cardiovascular disease management due to their ability to selectively block leukocyte-endothelial interactions involved in inflammatory cell recruitment. Herein, seven novel anti-VCAM-1 monoclonal antibodies (mAbs) generated from phage display biopanning were tested using a series of in vitro models of cell recruitment to determine their potential utility for treating atherosclerosis. Methods and Results We assessed the inhibitory effects of the test antibodies on cell adhesion and transmigration using a series of in vitro assays that incorporated three-dimensional microfluidics and collagen hydrogel models. In summary, each of our mAb candidates were found to reduce RAW264.7 monocyte adhesion to activated SVEC4–10 endothelial monolayers under static conditions. Subsequently, the three most effective candidates from this assay—2E2, 3C12, and 3H4—were shown to inhibit monocyte adhesion to endothelial microvessels under flow conditions and monocyte transmigration into endothelialized gel matrices under static conditions.
Conclusion
These results indicate that our novel anti-VCAM-1 mAbs can effectively inhibit monocyte adhesion and transmigration in vitro, supporting the therapeutic rationale of VCAM-1 immunoblockade for the targeted treatment of atherosclerosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Environment and Science, Griffith University, 170 Kessels Road, Nathan, Queensland 4111, Australia.
- Queensland Quantum and Advanced Technologies Research Institute, Griffith University, 170 Kessels Road, Nathan, Queensland 4111, Australia.
- School of Chemistry and Molecular Biosciences, The University of Queensland, 280-284 Sir Fred Schonell Drive, St Lucia, Queensland 4072, Australia.
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, 280-284 Sir Fred Schonell Drive, St Lucia, Queensland 4072, Australia.
Förderung
- National Health and Medical Research Council
- National Heart Foundation of Australia
- Promoting Women Fellowship from the University of Queensland
- Griffith University PhD scholarship
- Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program
Zitieren
APA
Pickett, J. R., Zacchi, L. F., Perera, B., Wu, Y., & Ta, H. T. (2025). Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation. Antibody Therapeutics, 8(4), 350-363. https://doi.org/10.1093/abt/tbaf025
Vancouver
Pickett JR, Zacchi LF, Perera B, Wu Y, Ta HT. Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation. Antibody Therapeutics. 2025;8(4):350-363. doi:10.1093/abt/tbaf025
BibTeX
@article{Pickett2025,
author = {Pickett, Jessica R and Zacchi, Lucia F and Perera, Binura and Wu, Yuao and Ta, Hang Thu},
title = {Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation},
journal = {Antibody Therapeutics},
year = {2025},
volume = {8},
number = {4},
pages = {350--363},
doi = {10.1093/abt/tbaf025}
}
EUVIMED